# **Supplementary Material**

2

3

4

1

# Farnesoid X Receptor via Notch1 directs asymmetric cell division of Sox9+

cells to prevent development of liver cancer in a mouse model

5

- 6 Mi Chen¹, Chenxia Lu²\*, Hanwen Lu¹\*, Junyi Zhang¹, Dan Qin¹, Shenghui Liu¹, Xiaodong Li³ and
- 7 Lisheng Zhang<sup>1</sup>

8

- 9 <sup>1</sup>College of Veterinary Medicine / College of Biomedicine and Health, Huazhong Agricultural University,
- 10 Wuhan, 430070, China.

11

- <sup>2</sup>The Clinical Medical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine,
- 13 Wuhan, 430065, China.

14

15

<sup>3</sup>Hubei Provincial Hospital of TCM, Hubei Provincial Academy of TCM. Wuhan 430061, China.

16

17

\*These authors contributed equally to this work.

## 18 Corresponding author:

- 19 Lisheng Zhang, College of Veterinary Medicine / College of Biomedicine and Health, Huazhong
- 20 Agricultural University, Wuhan, 430070, China. Tel: 86-27-87282091, Fax: 86-27-87280470. E-mail:
- 21 lishengzhang@mail.hzau.edu.cn.

### 22 Supplemental Figures

# 24 Figure . S1

23

25

27

28

30

36

37





Fig. S1 Representative photomicrographs of liver lesions from 12 month-old WT and FXR-KO mice. a

Liver tumors in 12-month-old WT and FXR-KO mice. Circles show the tumor nodules.


### 29 **Figure . S2**



31 **Fig. S2** Hepatic FXR Levels Inversely Correlate with Notch1 Levels in CCl4 induced liver injury model.


- mice were injected with Control or CCl<sub>4</sub> (2ml/kg body weight, i.p., twice a week for 2 weeks). a
- 33 Expression of FXR and Notch1 mRNAs in livers of WT and CCl<sub>4</sub>-treated mice. **b** Expression of FXR
- and Notch1 in WT and CCl<sub>4</sub>-treated mice was examined by western blotting, normalized to GAPDH.
- Data were presented as mean  $\pm$  SEM (N = 4) of three independent experiments. \*P < 0.05; \*\*p < 0.01.

#### Figure . S3



**Fig. S3** The BrdU pulse-chase assay analysis in liver cancer cells. **a** After two weeks the BrdU pulse, mitotic cells were stained for BrdU labeling by immunofluresence. A representative image is shown in which all of the cells at various degrees of condensed chromatin were BrdU-positive (red). Scale bar: 50μm.

#### Figure . S4



**Fig. S4** FXR activation inhibits Notch1 expression and protects from CCl<sub>4</sub> induced liver injury. Liver injury was induced by CCl<sub>4</sub> administration (i.p. 2 ml/Kg body weight, twice a week for 2 weeks). CCl<sub>4</sub> mice were randomized to receive GW4064 (50 mg/Kg once every two days for 2 weeks) or Control (4:1 of PEG-400 and Tween 80). **a** serum level of ALT (left) and AST(right) were calculated. **b** 

Representative liver sections from WT or FXR-KO mice stained with H&E. c Quantitative real-time PCR analysis shown expression of SHP (left) and Notch1 (right), in WT and FXR-KO mice treated as indicated. d Western blotting analysis of NICD1, Notch1 and Numb protein levels in livers of WT and FXR-KO mice, normalized to LaminB or GAPDH. Data represented the mean  $\pm$  SEM (N = 4). Statistical significance of differences between each treatment and control group (\*p < 0.05; \*\*p < 0.01) were determined. 

# **Supplemental Tables**

Table S1 The siRNA-FXR and negative control (Si-NC) sequences

siRNA names	Sequences (5'-3')			
si-FXR sense	GGAAGAAAGAAUUCGAAAUTT			
si-FXR antisense	AUUUCGAAUUCUUUCUTT			
negative control sense	UUCUCCGAACGUGUCACGUTT			
negative control antisense	ACGUGACACGUUCGGAGAATT			

# Table S2 The primers used for reverse transcription, PCR and qPCR

Primer names	Sequences (5'-3')			
H-GAPDH-Forward	CTCTGGTAAAGTGGATATTG			
H-GAPDH-Reverse	CTCTGGTAAAGTGGATATTG			
H-FXR-Forward	ATGCCTGTAACAAAGAAGCCCC			
H-FXR-Reverse	CACACAGTTGCCCCCGTTTTTA			
H-SHP-Forward	GTCCAGCTATGTGCACCTCATC			
H-SHP-Reverse	TTCCTGAGGAAGGCCACTGT			
H-Notch1-Forward	GTCAACGCCGTAGATGACC			
H-Notch1-Reverse	TTGTTAGCCCCGTTCTTCAG			
H-Bsep-Forward	GGAGCATTGACAACAAGACT			
H-Bsep-Reverse	CATTTGTAATCTGTCCCACC			
Chip-Notch1-Forward	TGCCTGGCTGTTACATAA			
Chip-Notch1-Reverse	ATAATCTGGCCTCACTTCTGC			
m-36B4-Forward	TGGAGACAAGGTGGGAGCC			
m-36B4-Reverse	CACAGACAATGCCAGGACGC			
m-SHP-Forward	CCTCTACCCTCAAGAACATTCCA			
m-SHP-Reverse	TTCAGTGATGTCAACGTCTCCC			
m-Notch1-Forward	TGAATGGAGGGAGGTGCGAAGT			
m-Notch1-Reverse	GTGCTGAGGCAAGGATTGGAGT			
m-FXR-Forward	TCCGGACATTCAACCATCAC			
m-FXR-Reverse	TCACTGCACATCCCAGATCTC			

# **Table S3** The primers used for the expression vector construction

Primer names	Sequences (5'-3')
H-Notch1-OE-Forward	GGGGTACCATGCACCTGGATGCCGCTGACCTG
H-Notch1-OE-Reverse	CCCTCGAGCTTGAAGGCCTCCGGAATGCG
pGL3-Notch1 FXRE-wt Forward	GGGGTACCGGCAGTCGCACCCGATCAGCA
pGL3-Notch1 FXRE-wt Reverse	GCAAGCTTAGCGCGGGCAGCAGCGCCAGGCAGAGC
pGL3-Notch1 FXRE-mut Forward	GCGCGTCAAACAAGATGTTACCCCAGG
pGL3-Notch1 FXRE-mut Reverse	CCTGGGGTAACATCTTGTTTGACGCGC

# Table S4 The EMSA reaction system

	NC reaction	Sample reaction	Cold competitor	Mutant cold competitor	Super-Shift
Nuclease-Free Water	7	5	1	1	4
5×binding buffer	2	2	2	2	2
nuclear protein	0	2	2	2	2
Labeled probe	1	1	1	1	1
Unlabeled probe	0	0	4	0	0
Unlabeled mutated probe	0	0	0	4	0
FXR Antibody	0	0	0	0	1
Total volume(μl)	10	10	10	10	10